Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

NeuroOp Guru

The Residency Report

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

News

All News

Contributors

Money Matters

Media

All Videos

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

Articles

From Nobel laureates to AI-driven research, the Wilmer Eye Institute honors a century of transforming vision science and care.

Wilmer Eye Institute marks 100 years: honoring the past, shaping the future

Kodiak Sciences showcases KSI-101, a potential new treatment for macular edema, at the 2025 IOIS Congress, aiming to better support patient care.

Kodiak Sciences to present KSI-101 highlights at the 2025 Congress of the International Ocular Inflammation Society (IOIS)

The trial is evaluating KB803 for the treatment and prevention of corneal abrasions in dystrophic epidermolysis bullosa

Krystal Biotech doses first patient in phase 3 trial IOLITE

Qlaris Bio to showcase promising data on QLS-111, a novel glaucoma treatment, at the 2025 World Glaucoma Congress, highlighting its efficacy and safety.

Qlaris Bio to present new data on QLS-111 at the 2025 World Glaucoma Congress 

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

About

Advertise

Privacy

Editorial Info

Editorial Board

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times – Clinical Insights for Eye Specialists

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

View

Personal Finance

Alameda, CA-InSite Vision Inc. and Bausch & Lomb have signed a licensing agree-ment to develop InSite's product ISV-403 for the treatment of ocular bacterial infections.

Ocular bacterial treatment in development

Ocular bacterial treatment in development

Newsletter